Alzamend Neuro Regains Nasdaq Compliance
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
Stocks · News reference
Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of $(1.28) per share from
Alzamend Neuro Files Prospectus Related To The Resale Of Up To 98.4M Common Shares By Selling Stockholder
-SEC Filing
Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar